Chitosan Global

Home  /

The Most Effective Form of Chitosan for Microplastic Adsorption and Excretion

The Most Effective Form of Chitosan for Microplastic Adsorption and Excretion

The Most Effective Form of Chitosan for Microplastic Adsorption and Excretion

A Comprehensive Evidence-Based Analysis of Recent Scientific Research (2024-2025)

Prepared For: Public Health & Scientific Community

Research Scope: Peer-reviewed literature 2024-2025

Disclaimer: This white paper is for informational and educational purposes only. It is based on a synthesis of recent scientific studies. It does not constitute medical advice, diagnosis, or treatment. Individuals should consult with a healthcare professional before starting any new dietary supplement regimen, especially those with pre-existing medical conditions, allergies (specifically shellfish), or those who are pregnant or breastfeeding.

Executive Summary

This white paper synthesizes groundbreaking research from 2024 and 2025 regarding dietary interventions for microplastic mitigation. The analysis identifies specific parameters of chitosan—a naturally occurring cationic biopolymer derived from chitin in crustacean shells (and increasingly from sustainable insect and fungal sources)—that maximize the adsorption and excretion of ingested microplastics (MPs) from the human gastrointestinal tract.

Key Findings:

  • Optimal Specification: High molecular weight chitosan (100–300 kDa) with a 90% degree of deacetylation (DDA) demonstrates superior efficacy.
  • Efficacy: A 0.8g dose taken immediately before meals resulted in a 45% increase in total microplastic excretion in human clinical trials.
  • Mechanism: Efficacy relies on pH-dependent gel formation, protonation in stomach acid, and physical entrapment (“molecular sieve” effect).
  • Broad Spectrum: Proven effective for capturing 9 major types of microplastics, including Polyethylene (PE), PET, and Rayon.
  • Safety: Chitosan holds FDA GRAS status and demonstrated an excellent safety profile in recent trials with minimal side effects.

Table of Contents

  1. Introduction

The ubiquity of microplastics (MPs) in the global environment has precipitated a silent health crisis. Defined as plastic particles smaller than 5mm, MPs have infiltrated every level of the food chain. Humans are continuously exposed via inhalation, dermal contact, and, most significantly, ingestion through contaminated food and water. Recent estimates suggest the average person ingests the mass equivalent of a credit card in plastic every week.

While source reduction remains the primary environmental goal, the accumulation of MPs in human tissues—including the placenta, liver, lungs, and blood—demands immediate physiological interventions. The potential for MPs to act as vectors for toxins, disrupt endocrine function, and induce inflammation underscores the urgency for safe, effective dietary strategies to limit bioavailability.

This white paper focuses on the most promising dietary agent identified in 2024-2025 literature: Chitosan. By reviewing key studies, including the landmark 2025 human trial by Casella et al. and the mechanistic animal study by Liu & Shimizu, we provide an evidence-based analysis of the specific forms and protocols required to effectively mitigate microplastic body burden.

  1. Microplastic Exposure and Health Impacts

2.1 Routes of Human Exposure

Ingestion represents the dominant pathway for microplastic entry. Dietary staples have been identified as significant vectors.

Source Estimated Concentration Primary Polymer Types
Seafood (Shellfish) High (Whole organism consumption) PE, PP, PET
Sea Salt 0 – 1,674 particles/kg PE, PP
Bottled Water 325 particles/L (avg) PET, PP
Air (Inhalation) Variable (Indoor > Outdoor) Synthetic Fibers (Rayon, Polyester)

2.2 Particle Size and Translocation

Particle size is the critical determinant of physiological fate. Research confirms that the intestinal barrier is permeable to specific size ranges:

  • >150 μm: Generally retained in the gut lumen or mucus layer; primary candidates for excretion via dietary binders.
  • <150 μm: Can cross the intestinal epithelial barrier via paracellular or transcytosis pathways.
  • <20 μm: Capable of infiltrating organs such as the liver and kidneys.
  • <100 nm (Nanoplastics): Can penetrate cell membranes, access the bloodstream, and potentially cross the blood-brain barrier.

2.3 Health Effects

Recent toxicological data links MP accumulation to systemic health risks:

  • GI Tract: Physical abrasion, disruption of the mucus layer, and alteration of gut microbiota (dysbiosis).
  • Inflammation: Elevation of pro-inflammatory cytokines (IL-1β, IL-6, IL-8) in intestinal tissues.
  • Cardiovascular: Recent findings correlate MP presence in atheromas with increased risk of cardiovascular events.
  • Bioaccumulation: Persistence in human tissues suggests metabolic clearance is inefficient without intervention.
  1. Chitosan Properties and Mechanisms

3.1 Chemical Structure and Sources

Chitosan is a linear polysaccharide composed of randomly distributed β-(1→4)-linked D-glucosamine (deacetylated unit) and N-acetyl-D-glucosamine (acetylated unit). It is produced by the deacetylation of chitin, the structural element in the exoskeletons of crustaceans (shrimp, crabs) and cell walls of fungi.

The presence of primary amino groups (-NH2) at the C2 position renders chitosan a cationic polymer—a unique property among dietary fibers that is central to its MP-binding capability. This positive charge allows chitosan to bind to negatively charged molecules, including fats, heavy metals, toxins, and microplastics.

Modern Chitosan Sources:

⚠️ IMPORTANT: Shellfish Chitosan NOT Recommended for Dietary Supplements
While shellfish-derived chitosan (from shrimp and crab shell waste) is cost-effective for industrial applications such as environmental remediation, water treatment, and agriculture, it should NOT be used for human dietary supplements due to:

  • Heavy Metal Contamination: Shellfish accumulate heavy metals (lead, mercury, cadmium, arsenic) from ocean pollution, which concentrate in their shells and persist through chitosan extraction.
  • Batch Inconsistency: Variable quality and contamination levels between production batches make shellfish chitosan unsuitable for pharmaceutical or dietary use.
  • Safety Concerns: Even with purification, trace heavy metals may remain, posing long-term health risks when consumed regularly.

Mushroom Chitosan (RECOMMENDED – Plant-Based): 100% fungal-derived biopolymer from mushroom cell walls (typically Aspergillus niger). Clean, consistent, and free from marine-sourced heavy metals. Suitable for individuals with shellfish allergies and preferred for all dietary supplement applications. Excellent safety profile with predictable batch-to-batch consistency. Sustainable and scalable production without ocean resource depletion.

BSF (Black Soldier Fly) Chitosan (RECOMMENDED – Premium Grade): Pharmaceutical-grade chitosan extracted through sustainable insect bioprocessing. Ultra-high purity (>99.9%) with exceptional batch consistency. Grown in controlled conditions free from environmental contaminants. Perfect for advanced formulations requiring enhanced solubility and custom derivatives (trimethyl chitosan, chitosan oligosaccharide, chitosan hydrochloride). Represents the gold standard for human consumption with guaranteed purity and traceability. Cutting edge of sustainable biopolymer production.

3.2 Key Parameters

Not all chitosan is effective. Efficacy depends on specific physicochemical parameters:

Property Range Tested Optimal Spec Functional Effect
Molecular Weight (MW) 50 – 400 kDa 100 – 300 kDa Determines gel strength and bridging capability. Too low = weak gel; Too high = poor solubility.
Deacetylation Degree (DDA) 70% – 95% 85% – 95% (90%) Determines charge density (protonation sites). Higher DDA = stronger binding.
Viscosity 50 – 200 cPs 90 – 120 cPs Correlates with MW; ensures stable hydrogel formation.

3.3 Mechanisms of MP Binding

The removal of microplastics by chitosan follows a sequential, pH-dependent mechanism:

Step 1: Stomach Dissolution (Acidic Phase, pH 2-3)
Upon ingestion, the amino groups on the chitosan backbone protonate (-NH3+). The polymer becomes soluble and forms a viscous, positively charged colloidal solution that disperses among stomach contents.

Step 2: Binding Interactions
The protonated chitosan interacts with MPs via:

  • Hydrogen Bonding: Between chitosan’s OH/NH groups and oxidized surface groups (carbonyls) on MPs.
  • Electrostatic Bridging: Binding to negatively charged impurities or biofilms on MP surfaces.
  • Hydrophobic Interactions: The polymer backbone interacts with nonpolar plastic surfaces.

Step 3: Gel Formation (Neutral Phase, pH 5-7.5)
As chyme enters the duodenum, pH rises. Chitosan’s solubility decreases, causing it to precipitate and form a 3D hydrogel matrix. This acts as a “molecular sieve,” physically entrapping the MP particles within the gel network.

Step 4: Excretion
The indigestible gel carrier moves through the colon, retaining the trapped MPs, which are subsequently excreted in feces, preventing re-absorption or translocation.

  1. Evidence from Recent Studies (2024-2025)

4.1 Animal Study: Liu & Shimizu (Nature Scientific Reports, April 2025)

This pivotal study assessed the efficacy of dietary chitosan in promoting the excretion of polyethylene (PE) microplastics in rats.

Parameter Control Group C

Chitosan Group
hit

Significance
Excretion Rate (0-144h) 83.7 ± 3.8% 115.6 ± 4.5% p < 0.05
Intestinal Retention 12.1 ± 0.5% 6.1 ± 0.5% p < 0.05
Fecal Weight Baseline Increased significantly p < 0.05

Note: Excretion rate >100% in the chitosan group implies the clearance of previously retained or environmental baseline MPs in addition to the experimental dose.

4.2 Human Clinical Study: Casella et al. (2025)

This study represents the first preliminary trial in humans using PCC (Procambarus clarkii) chitosan to enhance MP excretion.

  • Participants: 10 healthy volunteers.
  • Intervention: 0.8g chitosan (100-140 kDa, 90% DDA) taken immediately before a standardized meal.
  • Results: MP excretion significantly increased for 9 major polymer types.
MP Type Baseline (Phase 1) Chitosan (Phase 2) % Change
Total MPs 654 ± 104 965 ± 165 +45%
Polyethylene (PE) 88 ± 37 165 ± 51 +88%
Rayon (RA) 167 ± 40 326 ± 78 +95%
PET 48 ± 24 98 ± 33 +104%
  1. Optimal Chitosan Specifications

Specification Recommendation

Molecular Weight: 100 – 300 kDa

Deacetylation Degree: 85% – 95%

Viscosity: 90 – 120 cPs

Source: Crustacean or Fungal (High Purity)

5.1 Molecular Weight Analysis

Recommendation: 100-300 kDa.
Evidence indicates that low molecular weight chitosan (<50 kDa) fails to form sufficiently robust gels to bridge and entrap particles. Ultra-high molecular weight chitosan may have solubility issues in the stomach. The 100-300 kDa range offers the optimal balance of solubility for initial dispersion and viscosity for subsequent gelation.

Note: Industrial suppliers like Chitosan Global and Biosynth offer multiple molecular weight grades optimized for different applications. For microplastic binding, medium-high MW grades (100-300 kDa) are specifically recommended.

5.2 Deacetylation Degree Analysis

Recommendation: 90% (Range 85-95%).
The DDA determines the number of free amino groups available for protonation. A higher DDA results in a higher cationic charge density in the stomach, enhancing electrostatic interactions with MPs. The human clinical trial confirmed efficacy at 90% DDA.

Higher deacetylation degrees enhance the cationic charge density, which is critical for binding negatively charged contaminants, including microplastics, heavy metals (lead, arsenic, mercury, cadmium), and lipids. Industrial-grade chitosan typically achieves 85-95% DDA through controlled deacetylation processes.

5.3 Viscosity Specification

Recommendation: 90-120 cPs.
Viscosity is a direct functional indicator of the polymer’s ability to create the “molecular sieve.” This specific range was validated in the Casella et al. study to effectively trap MPs without causing excessive gastrointestinal distress.

5.4 Source Selection and Purity

CRITICAL: Only mushroom-derived or BSF insect-derived chitosan should be used for dietary supplements.

For microplastic binding in dietary supplements, source selection is limited to contaminant-free options:

  • ❌ Shellfish Chitosan – NOT RECOMMENDED: Despite being cost-effective and widely available, shellfish-derived chitosan carries unacceptable risks for human consumption:
    • Possible heavy metal accumulation from ocean pollution (lead, mercury, cadmium, arsenic)
    • Significant batch-to-batch variability in purity and quality
    • Potential allergenicity for shellfish-sensitive individuals
    • Use restricted to industrial applications only (environmental remediation, agriculture, water treatment)
  • ✓ Mushroom/Fungal Chitosan – RECOMMENDED: Clean, allergen-free alternative with superior safety profile:
    • Free from marine-sourced heavy metal contamination
    • Consistent batch quality from controlled fermentation
    • Ideal for vegans, those with crustacean allergies, and the general population
    • Comparable or superior binding properties to shellfish chitosan
    • First choice for dietary supplement formulations
  • ✓ Insect (BSF) Chitosan – PREMIUM RECOMMENDED: Pharmaceutical-grade option with highest purity:
    • Ultra-high purity (>99.9%) with zero heavy metal contamination
    • Produced in controlled, traceable conditions
    • Superior batch consistency and quality assurance
    • Optimal for individuals seeking maximum bioavailability and safety
    • Enhanced derivatives available (chitosan oligosaccharide, etc.)
    • Gold standard for pharmaceutical and nutraceutical applications

Purity Standard: Minimum 95% chitosan content for dietary supplements (higher than industrial grade). Look for pharmaceutical-grade certification with Certificate of Analysis (COA) documenting heavy metal testing. All dietary chitosan must be from mushroom or BSF sources only.

  1. Dosing Protocol

EVIDENCE-BASED PROTOCOL

Dosage: 0.8g – 1.0g/meal

Frequency: 2–3 times daily (Max 3.0g/day)

Timing: Immediately before meals (5-15 minutes prior)

Administration: Take with 120ml (4oz) water

6.1 Optimal Dosage

The human trial utilized 0.8g per meal. This aligns with calculating a concentration of ~1mg/mL in the average stomach volume (800mL). Dosages significantly lower may result in a sparse gel network that allows MPs to escape, while significantly higher doses may cause constipation.

6.2 Critical Timing Protocol

Timing is the single most critical factor. Chitosan must be present in the stomach before the food matrix arrives to ensure: 1. Adequate dissolution and protonation in gastric acid. 2. Formation of the gel matrix coincident with the arrival of food-borne MPs.

Taking chitosan after a meal significantly reduces efficacy as the pH buffering of food may prevent proper polymer dissolution.

  1. Safety Profile

7.1 Regulatory Status

Authority Status Details
US FDA GRAS Generally Recognized As Safe for food use.
EU (EFSA) Approved Approved for food contact and supplements.
WHO Safe No ADI established (considered non-toxic).

7.2 Toxicology and Side Effects

Chitosan exhibits an extremely low toxicity profile. Animal studies show an LD50 >16 g/kg. In human trials, it is well-tolerated at doses up to 3g/day.

Potential Side Effects:

  • Mild constipation (preventable with adequate hydration – 8-10 glasses of water daily).
  • Flatulence or bloating (rare, typically resolve within 3-5 days).
  • Very rare: mild nausea (take with food, reduce dose).
  • Reduced absorption of fat-soluble vitamins (A, D, E, K) and fatty acids – Mitigation: Take vitamins 4 hours apart from chitosan dosing.

Positive Health Effects Beyond MP Binding:

  • Heavy Metal Chelation: Chitosan binds to and helps remove negatively charged heavy metals including lead, arsenic, mercury, and cadmium from the digestive tract.
  • Lipid Management: The positive charge of chitosan binds to negatively charged fats and bile acids, supporting healthy cholesterol levels when combined with diet and exercise.
  • Prebiotic Fiber: Serves as a source of dietary fiber that feeds beneficial gut bacteria, supporting microbiome health.
  • Toxin Binding: May help bind and remove various environmental toxins and contaminants beyond microplastics.

7.3 Contraindications

Shellfish Allergy: Primary crustacean-derived chitosan is contraindicated. Patients with shellfish allergies must strictly use fungal-derived (mushroom or mycelium) chitosan or insect-derived (BSF) chitosan as allergen-free alternatives.

Pregnancy/Lactation: Insufficient human data. Consult healthcare provider before use.

Bleeding Disorders/Anticoagulant Use: Theoretical interaction with blood clotting. Monitor closely if taking warfarin or other anticoagulants.

  1. Effectiveness by Microplastic Type

The efficacy of chitosan varies by polymer type due to surface chemistry differences. The Casella et al. study provides granular data on this variance.

MP Type Effectiveness Observed Increase Mechanism Suitability
Polyacrylamide (PAM) ★★★★★ Very High +1100% High polar interaction
Polystyrene (PS) ★★★★★ Very High +700% Hydrophobic interaction
PET ★★★★★ Very High +104% Hydrogen bonding (ester groups)
Rayon (RA) ★★★★★ Very High +95% Fiber entanglement
Polyethylene (PE) ★★★★ High +88% Entrapment
Polypropylene (PP) ★★★ Moderate +10% Less surface polarity
Teflon (PTFE) ★ Minimal Non-significant Chemical inertness
  1. Synergistic Approaches

9.1 Dietary Fiber Combination

Insoluble dietary fibers (IDF) can enhance the “sweeping” effect of the chitosan gel. Combining chitosan with a diet rich in wheat bran or cellulose may reduce intestinal transit time, further limiting MP absorption opportunities.

9.2 Probiotic Support

Since MPs are known to cause dysbiosis, supporting the microbiome is crucial. However, probiotics should be taken 2-3 hours after chitosan to prevent the bacteria from being trapped in the chitosan gel matrix.

  1. Limitations and Future Research Needs

While current evidence is compelling, several gaps remain:

  • Sample Size: Human data is based on small cohorts (n=10). Large-scale RCTs are needed.
  • Nanoplastics: Current detection methods limit the ability to verify efficacy against particles <100nm, which pose the greatest translocation risk.
  • Long-term Safety: While general safety is established, the specific effects of long-term MP-chitosan complex excretion on colon health require monitoring.
  • Cellular Mechanism: Further research is needed to determine if chitosan can prevent cellular internalization at the microscopic level.
  1. Practical Recommendations

11.1 For Consumers

  1. Select the Right Product:Look for “Chitosan,” “90% Deacetylation,” and “Food Grade.” Verify the molecular weight is in the 100-300 kDa range. Avoid generic “Fat Binders” with added stimulants or undisclosed MW specifications.
  2. ⚠️ CRITICAL – Choose Your Source (Mushroom or BSF Only):
    • ✓ RECOMMENDED: Mushroom/Fungal Chitosan– Clean, allergen-free, consistent purity. Ideal for all consumers including vegans and those with shellfish allergies. First choice for dietary supplements.
    • ✓ PREMIUM RECOMMENDED: BSF Insect Chitosan– Pharmaceutical-grade with ultra-high purity (>99.9%). Maximum safety and bioavailability. Ideal for those seeking the highest quality.
    • ❌ AVOID: Shellfish-Derived Chitosan– May contain heavy metals from ocean pollution and has batch inconsistency. Suitable only for industrial use, NOT for human consumption.
  3. Follow the Protocol: Take 0.8g-1g (usually 2 capsules of 500mg each) immediately before your main meals. For DigestShield users: Take 4 capsules (4 × 200mg = 800mg) to reach the research-validated dose. For Pure Chitosan 3000 users, take 2-5 capsules (500 mg each) 5-15 minutes before eating a meal.
  4. Hydrate: Drink at least 8-10 glasses of water daily to support the gel formation and prevent constipation.
  5. Vitamin Timing: Take daily multivitamins or Omega-3s at breakfast if taking chitosan at lunch/dinner, or separate by 4 hours.
  6. Quality Verification: Purchase from reputable manufacturers that provide Certificates of Analysis (COA) showing:
    • Molecular weight (100-300 kDa)
    • DDA percentage (>90%)
    • Purity (>95%)
    • Heavy metal testing results(lead, mercury, cadmium, arsenic – all below detection limits)
    • Source verification (mushroom or BSF only)

Companies like Chitosan Global, Promecens, and Biosynth employ rigorous quality standards with proper source materials.

Commercial Product Example: DigestShield

Shield Nutraceuticals (parent company of Chitosan Global) has developed DigestShield, a comprehensive digestive health supplement that incorporates mushroom-derived chitosan specifically for microplastic and toxin binding.

DigestShield Formula:

  • 200mg Mushroom Chitosan per capsule (allergen-free, plant-based)
  • 20 plant-based digestive enzymes
  • 11 probiotic strains
  • 5 prebiotic compounds

Pure Chitosan 3000 Formula

  • Pure Mushroom Chitosan
  • 500mg/capsule

Unique Benefits:

  • Positively-charged chitosan shields against lectins, pesticides, pathogens, microplastics, and heavy metals
  • Helps digest gluten, dairy, soy, beans, fats, carbohydrates, and proteins
  • Supports gut microbiome balance while binding environmental contaminants
  • Prescribed by Dr. Tom Rogers (Board Certified in Integrative and Sports Medicine) for gut health optimization

Note: While DigestShield provides 200mg of chitosan per capsule (lower than the research-validated 800mg dose for maximum MP excretion), it offers the advantage of a comprehensive digestive support formula with mushroom-derived chitosan suitable for those with shellfish allergies. For targeted MP excretion, users may consider taking multiple capsules or supplementing with additional chitosan to reach the evidence-based 800mg threshold.

11.2 For Healthcare Providers

Consider recommending chitosan protocols for patients with high seafood intake or occupational exposure to plastics. CRITICAL: Prescribe ONLY mushroom-derived or BSF insect-derived chitosan for dietary supplement use. Do not recommend shellfish-derived chitosan due to heavy metal contamination and batch inconsistency.

Clinical Considerations:

  • Chitosan’s cationic properties enable multi-functional benefits: MP binding, heavy metal chelation (lead, mercury, arsenic, cadmium), lipid binding for cholesterol management, and serving as prebiotic fiber for gut microbiome support.
  • Source Requirements for Dietary Use:
    • ✓ Mushroom/fungal chitosan – First-line recommendation for all patients
    • ✓ BSF insect chitosan – Premium option for patients requiring pharmaceutical-grade purity
    • ❌ Shellfish chitosan – Contraindicated for dietary supplements; industrial use only
  • Verify product COA includes heavy metal testing showing undetectable levels of lead, mercury, cadmium, and arsenic.
  • For patients requiring maximum bioavailability or those with sensitive digestive systems, consider pharmaceutical-grade BSF chitosan or chitosan derivatives (chitosan oligosaccharide).
  • Monitor nutrient status in patients taking chitosan long-term, particularly fat-soluble vitamins.
  • Prescription Specification: “Mushroom-derived or BSF insect-derived chitosan, 100-300 kDa MW, 90% DDA, pharmaceutical grade, 800mg before meals”

Patient Education Points:

  • Emphasize the importance of source: Only mushroom or BSF chitosan is safe for dietary use
  • Warn against purchasing generic “chitosan” supplements that don’t specify non-shellfish source
  • Recommend brands that provide full transparency and COA documentation (e.g., Shield Nutraceuticals DigestShield with mushroom chitosan)
  1. Economic and Accessibility Considerations

Chitosan is a byproduct of the seafood industry and increasingly from sustainable insect farming operations, making it an economically sustainable and affordable supplement. The calculated cost for a standard protocol (1.6g/day) ranges from $12 to $24 per month, making it a highly accessible public health intervention compared to other medical treatments.

12.1 Pricing by Source

Chitosan Source Relative Cost Monthly Cost (1.6-2g/day) Dietary Supplement Use
Shellfish (Shrimp/Crab) Lowest $12-20 ❌ NOT RECOMMENDED
Industrial use only (heavy metal contamination, batch inconsistency)
Mushroom/Fungal Moderate $20-35 ✓ RECOMMENDED
All consumers, vegans, allergen-free, consistent quality
Insect (BSF) Premium $35-55 ✓ PREMIUM RECOMMENDED
Maximum purity (>99.9%), pharmaceutical-grade, optimal for sensitive individuals

Important Note: While shellfish-derived chitosan appears more affordable, the hidden costs of potential heavy metal exposure and health risks make it unsuitable and unsafe for dietary supplements. The slightly higher cost of mushroom or BSF chitosan is a worthwhile investment in purity and safety.

12.2 Sustainability and Supply Chain

Modern chitosan production leverages sustainable bioprocessing and controlled fermentation, making it an environmentally responsible choice:

  • Shellfish Chitosan (Industrial Applications Only): While it utilizes discarded shells from seafood processing waste, it is contaminated with heavy metals from ocean pollution and suffers from batch inconsistency. Reserved exclusively for non-human-contact applications: environmental remediation, water treatment, agriculture, and industrial flocculation.
  • Fungal/Mushroom Chitosan (RECOMMENDED for Dietary Use): Produced through controlled fermentation of mushroom mycelium (typically Aspergillus niger). Completely renewable and scalable without depleting marine resources. Free from marine contaminants and heavy metals. Consistent quality batch-to-batch. Suitable for organic certifications and vegan markets. Represents clean, sustainable biopolymer production.
  • Insect (BSF) Chitosan (PREMIUM RECOMMENDED for Dietary Use): Black soldier fly farming represents cutting-edge sustainable bioprocessing, converting organic waste streams into pharmaceutical-grade biomaterials with minimal environmental footprint. Grown in controlled, traceable conditions, ensuring zero contamination. Ultra-high purity exceeding pharmaceutical standards. Most sustainable option with closed-loop production system.

Leading manufacturers like Chitosan Global (a division of Shield Nutraceuticals), and Promecens Entosystems, combine nature’s genius with advanced technology to produce consistent, high-quality chitosan. For dietary supplements and human consumption, these companies provide exclusively mushroom-derived and BSF insect-derived chitosan, ensuring zero heavy metal contamination and consistent batch quality. Their commitment to using only clean, controlled sources ensures that chitosan supplementation supports both human health and planetary health without compromising safety.

Industrial vs. Dietary Grade Distinction:

  • Industrial Grade (Shellfish): Chitosan Global supplies shellfish-derived chitosan for environmental remediation, brownfield restoration, agricultural soil amendment, and water treatment where human consumption is not a factor.
  • Dietary/Pharmaceutical Grade (Mushroom & BSF Only): Shield Nutraceuticals and Promecens provide exclusively contaminant-free mushroom and BSF chitosan for dietary supplements, cosmetics, and medical applications where purity and safety are paramount.
  • For adsorbing microplastics’, we recommend our native BSF chitosan combined with a proprietary new derivative, Ionotropical Stable Chitosan. It is called Chitonova-MP.

12.3 Product Availability and Market Access

Chitosan supplements are widely available through multiple channels:

  • Direct-to-Consumer: Companies like Shield Nutraceuticals offer specialized formulations (e.g., DigestShield) with mushroom chitosan and complementary digestive health ingredients.
  • Online Retailers: Amazon, iHerb, and specialty supplement sites carry various chitosan brands.
  • Healthcare Providers: Integrative and functional medicine practitioners may prescribe or recommend specific pharmaceutical-grade formulations.
  • Bulk/Industrial: Chitosan Global supplies industrial-grade material for environmental remediation, agriculture, and custom formulation development.

Quality Assurance: When selecting products, look for companies that provide Certificate of Analysis (COA), third-party testing, and transparent sourcing information. Physician-recommended brands like DigestShield undergo rigorous quality control and are backed by clinical practitioners in integrative medicine.

  1. Conclusion

The convergence of recent animal and human research in 2024-2025 provides strong evidence that High Molecular Weight (100-300 kDa), 90% Deacetylated Chitosan is a safe and effective dietary intervention for microplastic mitigation. With a documented ability to increase MP excretion by 45-100% for major plastic types, it represents the most viable immediate solution for reducing the body burden of environmental plastics.

Chitosan’s unique cationic properties—stemming from its primary amino groups—enable it to bind not only microplastics but also heavy metals, dietary fats, and environmental toxins, making it a multifunctional health intervention. Modern production methods utilizing crustacean waste, fungal fermentation, and sustainable insect bioprocessing ensure that chitosan is both economically accessible and environmentally responsible.

The availability of multiple chitosan sources (shellfish, mushroom, and insect-derived) ensures that this intervention can be adapted to individual needs, including those with allergies, dietary restrictions, or preferences for premium pharmaceutical-grade formulations. Companies like Chitosan Global and Promecens exemplify how nature’s genius combined with human innovation creates solutions that protect both human and planetary health.

While source reduction of plastics remains the ultimate societal goal, chitosan supplementation offers individuals a scientifically validated, immediately accessible tool to protect their health in the interim. At a cost of $12-40 per month depending on source and quality, it represents one of the most affordable preventive health interventions available.

Final Recommendation

For optimal microplastic excretion enhancement:

  • Specification: 100-300 kDa molecular weight, 85-95% deacetylation degree (90% ideal), 90-120 cPs viscosity, produced in a ratio of Native Chitosan with Ionotropical Chitosan, from Black Soldier Fly or Fungal Source.
  • Source: Mushroom/Fungal (allergen-free), or BSF Insect (pharmaceutical-grade)
  • Dosage: 0.8-1.0 grams immediately before meals
  • Frequency: 2-3 times daily with main meals (maximum 3.0g/day)
  • Duration: Safe for continuous long-term use
  • Quality: Food-grade or pharmaceutical-grade from reputable manufacturers with COA documentation

This evidence-based protocol represents the current state-of-the-art in dietary microplastic mitigation.

References

  1. Liu, D., & Shimizu, M. (2025). Ingesting chitosan can promote excretion of microplastics. Scientific Reports, 15, 14041. https://doi.org/10.1038/s41598-025-96393-w
  2. Casella, C., et al. (2025). Preliminary Study on PCC-Chitosan’s Ability to Enhance Microplastic Excretion in Human Stools from Healthy Volunteers. PMC12248620.
  3. Wang, H., et al. (2024). Fighting microplastics: The role of dietary fibers in protecting health. Food Frontiers. https://doi.org/10.1002/fft2.437
  4. EFSA Panel on Contaminants in the Food Chain (CONTAM). (2016). Presence of microplastics and nanoplastics in food, with particular focus on seafood. EFSA Journal, 14(6), e04501.
  5. S. Food and Drug Administration. (2022). GRAS Notice (GRN) 997: Chitosan.
  6. Schwabl, P., et al. (2019). Detection of various microplastics in human stool: A prospective case series. Annals of Internal Medicine, 171(7), 453-457.
  7. Leslie, H. A., et al. (2022). Discovery and quantification of plastic particle pollution in human blood. Environment International, 163, 107199.
  8. Ragusa, A., et al. (2021). Plasticenta: First evidence of microplastics in human placenta. Environment International, 146, 106274.
  9. Chitosan Global. (2025). Industrial Biochemical Solutions for Environmental Restoration. Retrieved from https://chitosanglobal.com
  10. (2025). Nature’s Genius, Human Innovation: Sustainable Bio-Extraction of High-Value Biopolymers. Retrieved from https://promecens.com
  11. Shield Nutraceuticals. (2025). Black Soldier Fly (BSF) Chitosan: Pharmaceutical-Grade Biopolymer for Advanced Applications. Chitosan Global Division.
  12. Yan, Z., et al. (2022). Analysis of microplastics in human feces reveals a correlation between fecal MPs, inflammatory bowel disease status, and inflammatory cytokine levels. Environmental Science & Technology, 56(1), 414-421.
  13. Marfella, R., et al. (2024). Microplastics and nanoplastics in atheromas and cardiovascular events. New England Journal of Medicine, 390(10), 900-910.
  14. Jenner, L. C., et al. (2022). Detection of microplastics in human lung tissue using μFTIR spectroscopy. Science of the Total Environment, 831, 154907.
  15. Maezaki, Y., et al. (1993). Hypocholesterolemic effect of chitosan in adult males. Bioscience, Biotechnology, and Biochemistry, 57(9), 1439-1444.
  16. Yao, C. K., et al. (2022). Dietary fiber and the gut microbiome: mechanisms of action and clinical applications. Current Opinion in Biotechnology, 73, 199-206.

    Recent Posts

    wpChatIcon
    wpChatIcon